secwatch.observer — SEC 8-K summary
======================================

Issuer:     Abpro Holdings, Inc. (ABPO)
CIK:        0001893219
Form:       8-K
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001213900-25-121446
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abpro submits IND to FDA for phase 1 trial of ABP-102/CT-P72 in HER2+ cancers
-----------------------------------------------------------------------------

- IND filed for ABP-102/CT-P72, a HER2×CD3 T cell engager targeting HER2-positive solid tumors.
- Co-developed with Celltrion; phase 1 start expected in 1H 2026 pending FDA clearance.
- Preclinical data presented at AACR 2025 and SITC 2025 showed selective activity in HER2-high tumor models.
- First IND submission by Abpro for a solid tumor indication, advancing its immuno-oncology pipeline.
- Phase 1 study will evaluate safety, PK, and preliminary efficacy in dose-escalation and expansion cohorts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1893219/000121390025121446/0001213900-25-121446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1893219/000121390025121446/ea0269613-8k_abpro.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-121446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer